Abstract

O-linked N-acetylglucosamine transferase (OGT) expression is increased in various cancer types, indicating the potential importance of O-GlcNAcylation in tumorigenesis. Secretory clusterin (sCLU) is involved in cancer cell proliferation and drug resistance, and recently, liver X receptors (LXRs) and sterol response element binding protein-1 (SREBP-1) were reported to regulate sCLU transcription. Here, we found that sCLU is significantly increased in cervical cancer cell lines, which have higher expression levels of O-GlcNAc and OGT than keratinocytes. OGT knockdown decreased expression of LXRs, SREBP-1 and sCLU through hypo-O-GlcNAcylation of LXRs. Additionally, treatment with Thiamet G, O-GlcNAcase OGA inhibitor, increased expression of O-GlcNAcylation and sCLU, and high glucose increased levels of LXRs, SREBP-1 and sCLU in HeLa cells. Moreover, OGT knockdown induced G0/G1 phase cell cycle arrest and late apoptosis in cisplatin-treated HeLa cells, and decreased viability compared to OGT intact HeLa cells. Taken together, these findings suggest that OGT, O-GlcNAcylated LXRs, and SREBP-1 increase sCLU expression in cervical cancer cells, which contributes to drug resistance.

Highlights

  • Clusterin (CLU) is a highly conserved glycoprotein expressed ubiquitously in various tissue types, and has been implicated in aging, cancer progression, and several metabolic diseases [1, 2]

  • We found that levels of Secretory clusterin (sCLU) and O-linked N-acetylglucosamine transferase (OGT) mRNA expression were increased in HeLa, SiHa, C33A compared to HaCaT cells (Supplementary Figure 1)

  • These data suggest that OGT, O-GlcNAc, and sCLU expression is increased in cervical cancer cell lines and cervical cancer

Read more

Summary

Introduction

Clusterin (CLU) is a highly conserved glycoprotein expressed ubiquitously in various tissue types, and has been implicated in aging, cancer progression, and several metabolic diseases [1, 2]. SCLU acts as a molecular chaperone and promotes cell survival [5, 6], while sCLU is partially responsible for increased resistance of cancer cells to several chemotherapies due to its pro-survival functions [7,8,9,10]. CLU expression is regulated by metabolic signals, such as sterol regulatory element binding protein-1 (SREBP-1) [11,12,13], and hyperglycemia induces sCLU expression through the SREBP response element (SRE) but not by carbohydrate responsive element binding protein (ChREBP) in primary hepatocytes and hepatoma cell lines [14]. The role of O-GlcNAcylation in tumorigenesis and progression is becoming clearer, but several unanswered questions, such as its role in drug resistance, still remain

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.